Literature DB >> 21207908

Information to patients with malignant melanoma: a randomized group study.

Y Brandberg1, M Bergenmar, C Bolund, H Michelson, E Månsson-Brahme, U Ringborg, P O Sjödén.   

Abstract

An information programme for patients with cutaneous malignant melanoma, Stage 1, aiming at increasing satisfaction with information, was carried out at the Department of Oncology (Radiumhemmet). The programme consisted of a group meeting and a brochure. A total of 231 consecutive patients were included, and 149 (65%) reported interest in participation and were randomized to the Information group (n = 77) or to the Control group. A total of 67 patients (29%) were not interested (the NI-group). To evaluate the programme, the patients in the three groups completed questionnaires regarding satisfaction with information, knowledge of melanoma and psychological and psychosomatic variables before randomization and at the first visit for follow-up at Radiumhemmet. After the information programme, the Information group was significantly more satisfied with information, had a higher level of knowledge and a lower proportion requested further information as compared with the Control group. No differences were found on the psychological and psychosomatic variables.

Entities:  

Mesh:

Year:  1994        PMID: 21207908     DOI: 10.1016/0738-3991(94)90047-7

Source DB:  PubMed          Journal:  Patient Educ Couns        ISSN: 0738-3991


  2 in total

1.  "Melanoma: Questions and Answers." Development and evaluation of a psycho-educational resource for people with a history of melanoma.

Authors:  Nadine A Kasparian; Shab Mireskandari; Phyllis N Butow; Mbathio Dieng; Anne E Cust; Bettina Meiser; Kristine Barlow-Stewart; Scott Menzies; Graham J Mann
Journal:  Support Care Cancer       Date:  2016-07-27       Impact factor: 3.603

2.  [Psycho-oncological care for melanoma patients: conception and implementation].

Authors:  K Albrecht; F Meiss; T Zeiss; D Nashan; K Reuter
Journal:  Hautarzt       Date:  2013-12       Impact factor: 0.751

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.